Oral administration solid preparation containing component for reducing blood fat

Abstract

The invention relates to an oral drug preparation containing pravastatin, in particular to an oral solid formulation with reinforced effect of pravastatin, which comprises effective amount of pravastatin and pharmaceutical adjuvant, wherein the pharmaceutical adjuvant comprises an enwrap agent; the weight proportion of the pravastatin and the wrapping agent ranges from 1: 0.2 to 1: 10. The oral drug has the advantages of quick effects, reinforced active components and easy administration without uncomfortable feeling.

Description

technical field [0001] The invention relates to an oral solid preparation made of a drug containing a blood lipid-lowering component, which can significantly enhance the formulation stability and clinical blood-lipid-lowering effect of the component. Background technique [0002] Pravastatin sodium is an HMG-CoA reductase inhibitor, a hydrophilic statin hypolipidemic drug. After being absorbed in the body, it is hydrolyzed into a β-hydroxy acid structure, thereby inhibiting the activity of 3-methyl-3-hydroxyglutaryl coenzyme A (HMG-CoA) reductase, and reducing the synthesis of cholesterol in the body. Pravastatin (Pravastatin, Pravachol) was developed by Japan's Sankyo Company and was first launched in Japan in 1989 under the trade name "Mevalotin". As a national basic medical insurance drug and a national essential drug, it is currently widely used clinically. Due to the definite clinical curative effect of pravastatin on blood lipid regulation, although pravastatin is cur...

AI Technical Summary

Problems solved by technology

The stability of the three samples is very good under the premise of effective packaging at room temperature, but once they enter the human body, the stability has undergone unexpected drastic changes. This experimental reality makes us more aware that the pravastatin sodium according to The preparation methods taught by the prior art solve the problems of poor stability and poor drug efficacy in clinical use, not only can not achieve the purpose of improvement, but even the minimum maintenance of the original toxic and side effects cannot be achieved.

We can also get the following information from it: simply relying on the addition of alkaline pharmaceutical excipients in the preparation, whether it is a diluent, a lubricant or a surfactant, only simply improves the stability of the preparation in vitro, and cannot Fundamentally change the many problems after the disintegration of the drug in the body. Although the literature suggests that we can solve it by means of preparations, so far, no one or literature has reported how to solve it.